Health outcomes and cost-effectiveness of aprepitant in outpatients receiving antiemetic prophylaxis for highly emetogenic chemotherapy in Germany

This publication has 29 references indexed in Scilit:

• Incidence of chemotherapy‐induced nausea and emesis after modern antiemetics
  Cancer, 2004
• The oral NK1 antagonist, aprepitant, given with standard antiemetics provides protection against nausea and vomiting over multiple cycles of cisplatin-based chemotherapya combined analysis of two randomised, placebo-controlled phase III clinical trials
  European Journal Of Cancer, 2004
• The Oral Neurokinin-1 Antagonist Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting: A Multinational, Randomized, Double-Blind, Placebo-Controlled Trial in Patients Receiving High-Dose Cisplatin—The Aprepitant Protocol 052 Study Group
  Journal of Clinical Oncology, 2003
• Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy‐induced nausea and vomiting
  Cancer, 2003
• Nausea and emesis remain significant problems of chemotherapy despite prophylaxis with 5‐hydroxytryptamine‐3 antiemetics
  Cancer, 2003
• A randomized double-blind trial to compare the clinical efficacyof granisetron with metoclopramide, both combined with dexamethasone in the prophylaxis of chemotherapy-induced delayed emesis
  Annals of Oncology, 2003
• Recommendations for the Use of Antiemetics: Evidence-Based, Clinical Practice Guidelines
  Journal of Clinical Oncology, 1999
• Patient perceptions of the side-effects of chemotherapy: the influence of 5HT3 antagonists
  British Journal of Cancer, 1997
• Urinary serotonin metabolite excretion during cisplatin chemotherapy
  Cancer, 1993
• On the receiving end—patient perception of the side-effects of cancer chemotherapy
  European Journal of Cancer and Clinical Oncology, 1983